Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.37 (
DNA methyltransferase
)
4,983
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent studies have shown aberrant expression of
SOX11
in various types of aggressive B-cell neoplasms. To elucidate the molecular mechanisms leading to such deregulation, we performed a comprehensive
SOX11
gene expression and epigenetic study in stem cells, normal hematopoietic cells and different lymphoid neoplasms. We observed that
SOX11
expression is associated with unmethylated DNA and presence of activating histone marks (H3K9/14Ac and H3K4me3) in embryonic stem cells and some aggressive B-cell neoplasms. In contrast, adult stem cells, normal hematopoietic cells and other lymphoid neoplasms do not express
SOX11
. Such repression was associated with silencing histone marks H3K9me2 and H3K27me3. The
SOX11
promoter of non-malignant cells was consistently unmethylated whereas lymphoid neoplasms with silenced
SOX11
tended to acquire DNA hypermethylation.
SOX11
silencing in cell lines was reversed by the histone deacetylase inhibitor SAHA but not by the
DNA methyltransferase
inhibitor AZA. These data indicate that, although DNA hypermethylation of
SOX11
is frequent in lymphoid neoplasms, it seems to be functionally inert, as
SOX11
is already silenced in the hematopoietic system. In contrast, the pathogenic role of
SOX11
is associated with its de novo expression in some aggressive lymphoid malignancies, which is mediated by a shift from inactivating to activating histone modifications.
...
PMID:Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. 2173 49
